Amorolfine (3-[p-(1,1-dimethylpropyl)-phenyl]2-methyl-propyl-2,6-cis dimethylmorpholine hydrochloride; Ro 14-4767/002) shows activity against fungi pathogenic to plants, animals and humans (Polak and Dixon 1987). Given here is a resume of preclinical findings with this drug as well as a summary of published clinical data. In vitro the spectrum against representative species pathogenic for humans was defined measuring fungistatic as well as fungicidal effects. In vivo studies were conducted using models of dermatophytosis, vaginal candidosis and various organ mycoses.
KeywordsAntifungal Activity Tinea Pedis Local Adverse Effect Mycological Cure Mucor Circinelloides
Unable to display preview. Download preview PDF.
- Galimberti R, Garcia A, Milicich R, Cuomo G, Bonino MV, Flores V, Traballi CA (1988) Amorolfine (Ro 14-4767) a new trend for the treatment of tinea pedis. In: Torres-Rodríguez JM (ed) Proceedings of X congress of international society for human and animal mycology, Barcelona. JR Prous, Barcelona, pp 223–226Google Scholar
- Gip L (1989) In vitro studies of the antifungal activity of amorolfine, a phenylpropyl morpholine. Adv Ther 6: 26–38Google Scholar
- Mensing H, Splanemann V (1988) Evaluation of the antimycotic activity of the pathological substance under the nail after treatment with Ro 14-4767 nail lacquer. Revista Ibérica de Micológia 5 (Suppl 1): 20Google Scholar
- Nolting S (1988) Double-blind, randomized study comparing 3 concentrations (0.125, 0.25, 0.5%) of Ro 14-4767 and bifonazole 1% creams in patients with dermatomycosis. Revista Ibérica de Micológia 5 (Suppl 1): 19Google Scholar
- Odds FC, Webster CE, Abbott AB (1984) Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole, and vibunazole (Bay n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother 14: 105–114PubMedCrossRefGoogle Scholar
- Parissis N, Noutsis C, Rigopoulos D (1987) A single dose treatment of vaginal mycosis with the morpholine derivative Ro 14-4767. In: Berkarda B, Kuemmerle H-P (eds) Progress in antimicrobial and anticancer chemotherapy, vol. II. Ecomed, Munich, pp 1576–1578Google Scholar
- Polak A (1982b) Experimental activity of a new antimycotic. Curr Chem Immunother. Proceedings of the 12th international congress of chemotherapy, Florence, 19–24 July 1981, pp 1023–1025Google Scholar
- Polak A (1983) Antifungal activity in vitro of Ro 14-4767/002, a phenylpropylmorpholine. Sabouraudia 21:205–213Google Scholar
- Polak A, Dixon DM (1987) Antifungal activity of amorolfine (Ro 14-4767/002) in vitro and in vivo. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 554–573Google Scholar
- Reinel D (1988) Double-blind, randomized, multicentre trial of 2% vs. 5% Ro 14-4767 nail lacquer in patients suffering from onychomycosis. Revista Ibérica de Micológia 5 (Suppl 1): 93Google Scholar
- Rohde E, Zaug M, Hartmann D (1987) Preliminary clinical experience with Ro 14-4767 (Amorolfine) in superficial mycoses. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 575–582Google Scholar
- Scharlau L, Goldberg M, Lutziger H, Probst H, Schaal HJ (1987) Double-blind, randomized multicentre, dose-finding trial comparing three single doses (10, 25 and 50 mg) of amorolfine in patients suffering from vaginal mycosis. In: Berkarda B, Kuemmerle H-P (eds) Progress in antimicrobial and anticancer chemotherapy, vol. II. Ecomed, Munich, pp 1573–1575Google Scholar